Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

South African Journal of Psychiatry

Field Value
Title Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
Creator Rodrigues, Janine Lowton, Karishma
Subject Psychiatry; Neuropsychiatry; Neuropsychology; Neurology; Infectious diseases HIV-associated neurocognitive disorders; BNCE; IHDS; dolutegravir; neurocognitive screening; neurocognitive impairment; South Africa.
Description Background: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART). Dolutegravir-based regimens are the first line of treatment for adult HIV-positive patients. Controversies exist regarding the neurocognitive effects of dolutegravir. Evidence regarding the neurocognitive effects of dolutegravir is important, in support of its use in patients with HIV-associated neurocognitive disorders (HAND).Aim: This study aimed to describe the change in cognitive function using the International HIV Dementia Scale (IHDS) and Brief Neuropsychological Cognitive Examination (BNCE) in HIV positive, treatment naïve patients before and 3 months after initiation of ART using a dolutegravir-based regimen.Setting: The HIV initiation clinic of Hillbrow Community Health Centre in Johannesburg.Methods: This prospective, quantitative cohort study assessed adult HIV-positive patients who were ART naïve being initiated on a dolutegravir-based regimen, using the BNCE and IHDS at baseline and after 3 months of treatment.Results: Neurocognitive test results of 26 participants showed significant improvements for IHDS (Z = 1.84, p = 0.033) and time to complete BNCE (Z = 2.47, p = 0.007). BNCE total results showed improvements that were not significant (Z = 1.44, p = 0.075); however, Part 2 of the BNCE reflecting that of executive function showed significant improvements (Z = 66.5, p = 0.043).Conclusion: The trend of neurocognitive function is towards improvement in HIV-positive treatment naïve patients who receive 3 months of dolutegravir-based ART.Contribution: The findings support the use of dolutegravir-based regimens in the treatment of patients with HIV-associated neurocognitive disorders.
Publisher AOSIS
Contributor Professor Neville Pillay Dr Shona Fraser
Date 2023-09-28
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Prospective, quantitative, and descriptive cohort study
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajpsychiatry.v29i0.2071
Source South African Journal of Psychiatry; Vol 29 (2023); 8 pages 2078-6786 1608-9685
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
Coverage South Africa; Gauteng June 2021 - July 2022 Age; gender; HIV positive; years of education; cd4 count; viral load
Rights Copyright (c) 2023 Janine Rodrigues, Karishma Lowton